New Hope for “The Deadliest Hepatitis”: Dual Therapy Shows Promise in Phase II Trial

January 26, 2026

A potential turning point has arrived in the fight against Hepatitis D (HDV), widely considered the most aggressive form of viral hepatitis. Results from the Phase II SOLSTICE trial, recently published in The New England Journal of Medicine, reveal that a novel combination of investigational drugs—tobevibart and elebsiran—can significantly reduce viral levels and improve liver health in patients living with this chronic condition.

The study, which spanned 20 centers across nine countries, marks a critical step forward for a patient population that has long faced limited treatment options and a high risk of progressing to liver failure or cancer.

The “Silent Accomplice”: Understanding Hepatitis D

To understand the significance of the SOLSTICE trial, one must first understand the unique nature of the Hepatitis D virus. Unlike Hepatitis A or B, HDV is a “satellite virus.” It cannot exist on its own; it requires the presence of the Hepatitis B virus (HBV) to replicate and infect liver cells.

When a person is co-infected with both HBV and HDV, the disease progression is often faster and more severe than with HBV alone. For decades, the medical community has struggled to find a highly effective, well-tolerated treatment for HDV, often relying on interferon-based therapies that carry grueling side effects and inconsistent success rates.

“Hepatitis D is often called ‘the deadliest’ because of how rapidly it can scar the liver,” says Dr. Elena Rossi, a hepatologist not involved in the study. “Seeing virologic suppression rates this high in a Phase II trial is not just a statistical win; it’s a beacon of hope for patients who felt they were running out of time.”

The SOLSTICE Trial: Study Design and Key Findings

The SOLSTICE trial evaluated two different approaches: a monotherapy (tobevibart alone) and a dual therapy (tobevibart plus elebsiran). Tobevibart is a monoclonal antibody designed to block the virus from entering liver cells, while elebsiran is a small interfering RNA (siRNA) designed to stop the virus from producing the proteins it needs to survive.

The Study Population

The trial enrolled participants with chronic HDV (documented for at least six months) who showed signs of active liver inflammation, indicated by elevated alanine aminotransferase (ALT) levels and high viral loads (HDV RNA ≥500 IU/mL). The average age of participants was in the mid-40s, representing a demographic often in the prime of their working and family lives.

Measuring Success

Researchers looked for a “combined response,” which requires two things to happen simultaneously:

1. Virologic Improvement: A significant drop in the amount of HDV in the blood.

2. ALT Normalization: A return of liver enzymes to normal levels, indicating reduced liver cell damage.

The Results at 24 and 48 Weeks

The data showed rapid and sustained improvements:

While the monotherapy showed a slightly higher “combined response” at 48 weeks, the combination group was more successful at driving the virus down to undetectable levels (66%). In the world of chronic viral infections, reaching “undetectable” status is a primary goal for preventing long-term organ damage.

Safety and Tolerability

One of the most encouraging aspects of the SOLSTICE trial was the safety profile. Traditional treatments for hepatitis have been notoriously difficult for patients to complete due to severe fatigue, depression, and flu-like symptoms.

In this trial, both the dual therapy and monotherapy were well tolerated. The most common side effects reported were mild chills or flu-like symptoms, which typically resolved quickly. Crucially, there were no “ALT flares”—sudden, dangerous spikes in liver inflammation—which can sometimes occur when the immune system begins attacking a virus during treatment.

Public Health Implications and Practical Reality

For the estimated 12 to 70 million people worldwide living with HDV, these findings suggest that a more manageable treatment regimen may be on the horizon.

“If these results hold up in larger studies, we are looking at a move toward ‘precision virology,'” says Dr. Rossi. “By attacking the virus from two different angles—blocking entry and stopping production—we may finally be able to manage HDV as a chronic, controllable condition rather than a death sentence.”

What This Means for Patients

• Screening is Crucial: Many people with Hepatitis B are never tested for Hepatitis D. These results highlight why knowing your “D” status is vital; new treatments are only useful if the disease is diagnosed.

• The Path to Approval: While these results are promising, these drugs are still “investigational.” They are not yet available for general prescription.

• Continued Vigilance: Patients currently on HBV treatments should continue their regimens and talk to their specialists about the progress of HDV clinical trials.

Limitations and Next Steps

As with any Phase II trial, there are caveats. The study size was relatively small, and while the 48-week data is strong, long-term data (over several years) is needed to see if the virus remains suppressed after treatment stops.

Furthermore, while the “dual therapy” showed better results in making the virus undetectable, the “monotherapy” actually performed slightly better in the overall combined response metric at 48 weeks. Researchers are still investigating why the addition of a second drug didn’t create a wider gap in performance, though it may be related to how the body processes the medications over time.

The next phase of the journey is already underway. The ECLIPSE program, a Phase III trial, will test these therapies in a much larger, more diverse group of patients. This final stage of testing is what regulatory bodies like the FDA will use to decide if the drugs should be approved for public use.

References

• Study Citation: The New England Journal of Medicine. “Tobevibart and Elebsiran in Patients with Chronic Hepatitis D.” (Published 2025/2026).

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.